This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Martini, F. Articles by Abbate, R. Search for Related Content PubMed PubMed Citation Articles by Martini, F. Articles by Abbate, R. Pubmed/NCBI databases Medline Plus Health Information Lupus Social Bookmarking                         What's this?

Antiphospholipid antibodies (aPL) increase the potential monocyte procoagulant activity in patients with systemic lupus erythematosus

Istituto di Clinica Medica Generale e Cardiologia

A. Farsi

Istituto di Clinica Medica , University of Florence, Italy

AM Gori

Istituto di Clinica Medica Generale e Cardiologia

M. Boddi

Istituto di Clinica Medica Generale e Cardiologia

S. Fedi

Istituto di Clinica Medica Generale e Cardiologia

MP Domeneghetti

Istituto di Clinica Medica , University of Florence, Italy

A. Passaleva

Istituto di Clinica Medica , University of Florence, Italy

D. Prisco

Istituto di Clinica Medica Generale e Cardiologia

R. Abbate

Istituto di Clinica Medica Generale e Cardiologia

Lupus anticoagulant (LA) and anticardiolipin antibodies (aCL) are frequently detected in sera from patients affected by systemic lupus erythematosus (SLE). However, the role of antiphospholipid antibodies (aPL) in thrombus formation has not been defined as yet.

Twenty-two patients affected by SLE, all fulfilling the 1982 ARA revised criteria, and twenty healthy subjects were investigated for the presence of LA, aCL and other aPLs. Monocyte procoagulant activity-PCA (Tissue Factor production) was evaluated by one stage plasma recalcification time. In all patients the plasma levels of F1 + 2 and of plasmin ogen activator inhibitor (PAI) were also determined. Monocyte PCA was significantly higher in SLE patients with LA and/or aCL in comparison to SLE patients without LA and/or aCL (p < 0.01) and to controls (p < 0.05). However, no connection was observed between PCA expression by mononuclear cells and LA or aCL levels. No differences in F1 + 2 and PAI plasma levels were found between SLE patients with or without aPL and controls. In our SLE patients LA and/or aCL positivity appears strictly related to an increased monocyte activation that could play an important role in the occurrence of thrombotic events.

Key Words: procoagulant activity • monocyte • antiphospholipid antibodies • SLE

Lupus, Vol. 5, No. 3, 206-211 (1996)
DOI: 10.1177/096120339600500307


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R. A Asherson, S. S Pierangeli, and R. Cervera Is there a microangiopathic antiphospholipid syndrome? Ann Rheum Dis, April 1, 2007; 66(4): 429 - 432. [Full Text] [PDF]

				M. Bohgaki, T. Atsumi, Y. Yamashita, S. Yasuda, Y. Sakai, A. Furusaki, T. Bohgaki, O. Amengual, Y. Amasaki, and T. Koike The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-{beta}2Glycoprotein I antibodies Int. Immunol., November 1, 2004; 16(11): 1633 - 1641. [Abstract] [Full Text] [PDF]

				S S Pierangeli and E N Harris Probing antiphospholipid-mediated thrombosis: the interplay between anticardiolipin antibodies and endothelial cells Lupus, July 1, 2003; 12(7): 539 - 545. [Abstract] [PDF]

				J. H. Rand Molecular Pathogenesis of the Antiphospholipid Syndrome Circ. Res., January 11, 2002; 90(1): 29 - 37. [Abstract] [Full Text] [PDF]

				S. S. Pierangeli, R. G. Espinola, X. Liu, and E. N. Harris Thrombogenic Effects of Antiphospholipid Antibodies Are Mediated by Intercellular Cell Adhesion Molecule-1, Vascular Cell Adhesion Molecule-1, and P-Selectin Circ. Res., February 2, 2001; 88(2): 245 - 250. [Abstract] [Full Text] [PDF]

				A. Wierzbicki Lipids, cardiovascular disease and atherosclerosis in systemic lupus erythematosus Lupus, March 1, 2000; 9(3): 194 - 201. [Abstract] [PDF]

				S. Visvanathan and H. P. McNeil Cellular Immunity to {beta}2-Glycoprotein-1 in Patients with the Antiphospholipid Syndrome J. Immunol., June 1, 1999; 162(11): 6919 - 6925. [Abstract] [Full Text] [PDF]

				S. S. Pierangeli, M. Colden-Stanfield, X. Liu, J. H. Barker, G. L. Anderson, and E. N. Harris Antiphospholipid Antibodies From Antiphospholipid Syndrome Patients Activate Endothelial Cells In Vitro and In Vivo Circulation, April 20, 1999; 99(15): 1997 - 2002. [Abstract] [Full Text] [PDF]